Navigation Links
Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
Date:2/25/2008

Entry of Novel Therapies Including Rituxan/MabThera and Increased Uptake of CellCept Will Provide Effective Treatment Options, According to a New

Report from Decision Resources

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of high-priced branded agents will drive the systemic lupus erythematosus drug market to quadruple from approximately $325 million in 2006 to $1.4 billion in 2016.

The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the strongest drivers of market growth will be the formal approval of several therapies that target B cells, including Biogen Idec/Genentech/Zenyaku Kogyo's Rituxan/Roche's MabThera, as well as increased uptake of Roche/Aspreva Pharmaceuticals' branded immunosuppressant CellCept.

"The introduction of novel biologics, other targeted therapies, and immunosuppressants into the treatment regimens of patients with systemic lupus erythematosus will result in increased polypharmacy," said Amy Whiting, Ph.D., analyst at Decision Resources. "These agents will not replace existing therapies but rather be used in combination with existing drugs to provide more-effective and/or safer treatment."

The report finds that sales in the systemic lupus erythematosus drug market will experience a significant 24% annual increase between 2006 and 2011. Sales growth will then proceed at a slower pace of 9% annually from 2011 to 2016, owing to fewer new product launches, generic erosion of CellCept, and biogeneric erosion of Rituxan/MabThera.

About Systemic Lupus Erythematosus

Systemic lupus erythematosus is an autoimmune disease characterized by a complex pathophysiology that results in widespread tissue damage of multiple organ systems. The disease affects more than 537,000 people in the United States, France, Germany, Italy
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
2. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
3. The Branded Pharmaceutical Association Comments on Hydrocodone
4. FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients
5. ABR-Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio, Texas
6. LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission
7. Insurance Agents Call for State Senate to Improve Californias Health Care Reform Compromise
8. Allergic reactions to gadolinium-based contrast agents are rare, study finds
9. Germ-Fighting Inhaler Could Fend Off Bioterror Agents
10. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
11. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...mber 2009. Performing surgical operations without...become a reality. This is demonstrated by the rece...fice Transluminal Endoscopy Surgery), an innovativ...ing the body,s natural orifices. The results are a...orter hospital stay and faster recovery. Currently...
(Date:12/1/2009)...nosis of benign versus cancerous lesions, research...ews) -- When used with ultrasound, elastography he...t lesions, which reduces unnecessary biopsies, U.S... breast lesions that are biopsied turn out to be b..., "There,s a lot of room to improve specificity ...
(Date:12/1/2009)...CHO SANTA FE, Calif., Dec. 1 The f...redient in grapes acclaimed for its potential to f...marketplace. ,, (Photo: http://www.newscom.com...tp://www.newscom.com/cgi-bin/prnh/20091111/NY08935...veloped by ResVez, Inc. of Rancho Santa Fe, Calif....
(Date:12/1/2009)...NGELES, Dec. 1 Gooooooaaaaaal! ...kicks off its 2009/2010 growing season with a fres...nship with kids, soccer. Joy Fawcett - an award-w... the brand,s efforts to celebrate and mentor moms ...sponsorship expansion into Texas and a community-b...
(Date:12/1/2009)...in the December 2009 issue of the Journal of Thor...vival improvement among patients with metastatic l...as reported in controlled clinical trials. , Re...tients with stage IV non-small cell lung cancer (N...uate trends in survival between 1990 and 2005 to a...
Breaking Medicine News(10 mins):Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 3Health News:Ultrasound With Elastography May Cut Down on Biopsies 2Health News:First Resveratrol Nutrition Bar Hits the Market 2Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 2Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 3Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 4
... for Healthcare Philanthropy (AHP) today issued th...ctions for charitable donations proposed in the Ob...for Healthcare Philanthropy (AHP) opposes the prop...get to revive the economy, reform health care, rev...
...uncil on Disability (NCD) today released a report ...re provided to service members and veterans with P... Brain Injury (TBI). , , According to NCD Chairpe...still more. They are also putting unprecedented st...
...ssage Team ( www.mobilemassageteam.com ), a leadin...corporate wellness programs, promotional events, a...ny will be exhibiting at the Valley Forge Dental C...e chair massages to conference participants throug...
...rsity of California, San Francisco has shown that ...or of mortality among breast cancer patients, espe...pertension accounts for approximately 30 percent o...a Braithwaite, PhD, of the UCSF Helen Diller Famil...
...today that Humana Inc., one of the nation,s larges...ting process certifying its systems can deliver pa...ee on Operating Rules for Information Exchange (CO...mation with healthcare providers. The certificatio...
...th additional resources to manage through challeng...rch 4 /PRNewswire/ -- Experian(R), the global in...tegic alliance with Buxton, the industry leader in...ironment, market planners need better information,...
Other Medicine News:Health News:Association for Healthcare Philanthropy Opposes Limits on Charitable Tax Deductions 2Health News:Association for Healthcare Philanthropy Opposes Limits on Charitable Tax Deductions 3Health News:National Council on Disability Says More Needs to be Done for Service Members and Veterans With Post Traumatic Stress Disorder and Traumatic Brain Injury 2Health News:National Council on Disability Says More Needs to be Done for Service Members and Veterans With Post Traumatic Stress Disorder and Traumatic Brain Injury 3Health News:High blood pressure linked to earlier death among African-American breast cancer patients 2Health News:High blood pressure linked to earlier death among African-American breast cancer patients 3Health News:CAQH Announces Humana Inc. is Certified to Use CORE Phase I Rules 2Health News:CAQH Announces Humana Inc. is Certified to Use CORE Phase I Rules 3Health News:Experian Announces Alliance With Buxton to Expand Availability of Data and Analytics 2Health News:Experian Announces Alliance With Buxton to Expand Availability of Data and Analytics 3
(Date:11/30/2009)...Newswire-FirstCall/ -- Nektar Therapeutics (Nasdaq...e Masuoka, M.D. to Senior Vice President and Chief...y to Nektar,s President and Chief Executive Office...g leadership and highly effective clinical develop...advancing Nektar,s proprietary clinical pipeline, ...
(Date:11/30/2009)...wire-FirstCall/ -- Covance Inc. (NYSE: CVD ) tod...fray 21st Annual Health Care Conference on Wednesd... may access a live webcast of the presentation at ...oad any necessary software, please log on 10 minut...ceton, New Jersey, is one of the world,s largest a...
(Date:11/30/2009)...ewswire/ -- The Eleventh Annual Southeastern BIO I...harleston Place Hotel in the historic district of ... Liljestrand, Dr. Harry Guttman, and Dr. Jeremy M....l attend. SEBIO 2009 promises to bring innovative...trepreneurs, and service providers from around the...
Breaking Medicine Technology:Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 2Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 3Worlds First Cardiac Adult Stem Cell Patient Receives Infusion 4776 1Worlds First Cardiac Adult Stem Cell Patient Receives Infusion 4776 2Change to Win Statement on Minimum Wage Increase 52654 1NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 1NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 2NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 3NeurogesX Announces Preliminary Results of FDA Requested Qutenza 28TM 29 Study 4775 4
...SS WIRE)--Jun 7, 2007 - As a,follow up to ProtoKin...e related to cryopreserved (or frozen) cells treat...sity of Helsinki,Finland, ProtoKinetix has recent...whether AAGP(TM) treated cells could survive,after...menting on the results, ProtoKinetix,s Director of...
...for Both Efficacy and Safety, LEXINGTON, Mass., Ju...maceuticals, Inc. today announced final results fr...(testosterone,undecanoate), a long- acting injecta... treatment of male hypogonadism which the,Company ...he data,from the recently completed 48-week trial ...
Other Medicine Technology:Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's,AAGP 2Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6
...power supply is capable of producing up to 250 vol...ates in constant voltage or constant current with ...ically crosses over from one mode of operation to ... function, auto ranging 24-hour up/down timer allo...
...e electrophoresis and SDS-PAGE, to DNA Sequencing ...Power Supplies will support virtually any applicat...e available in four different output voltages:,200...stant voltage, current or power operating modes wi...
...300V, 4-400mA. 300 Plus: 300V, 4-500mA. Simple To ...ent mode. - Automatic crossover between modes prot... Designed for safety. - Extremely quiet operation....as well as blotting. - Extremely easy to program. ...
Max Power Power Supply
Medicine Products: